Physician profile
Jared Ellis
NPI 1790785756
$6,323.71
in general payments reported to CMS, 2019-2025
37 companies · $491 in 2025
The $491 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $962 · 2023: $3,010 · 2024: $1,861 · 2025: $491.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,361.72 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $784.80 | 2022-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $780.88 | 2022-2025 | Caplyta |
| Ucb, INC. | $526.28 | 2022-2024 | Briviact, Rystiggo, Nayzilam |
| Otsuka America Pharmaceutical, INC. | $364.92 | 2022-2025 | Rexulti, Nuedexta, Abilify Maintena |
| Pfizer INC. | $293.61 | 2022-2025 | |
| Lilly USA, LLC | $290.77 | 2022-2024 | Amyvid, Emgality, Reyvow |
| Sk Life Science, INC. | $287.72 | 2022-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $268.60 | 2022-2024 | Trintellix, Gammagard, Hyqvia |
| Alexion Pharmaceuticals, INC. | $246.22 | 2022-2024 | Ultomiris |
| Merz Pharmaceuticals, LLC | $243.30 | 2022-2024 | Xeomin |
| Neurocrine Biosciences, INC. | $192.39 | 2022-2025 | Ingrezza, Ongentys |
| Axsome Therapeutics, INC. | $184.40 | 2022-2025 | Auvelity, Sunosi |
| Sumitomo Pharma America, INC. | $167.47 | 2023-2024 | Aptiom |
| Lundbeck LLC | $155.38 | 2022-2025 | Vyepti, Rexulti |
| Teva Pharmaceuticals USA, INC. | $139.68 | 2022-2024 | Austedo Xr, Austedo |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Acorda Therapeutics, INC | $136.18 | 2023-2024 | Inbrija, Ampyra |
| Eisai INC. | $134.27 | 2022-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $126.99 | 2022 | |
| Csl Behring | $91.32 | 2022-2023 | Hizentra |
| Neurelis, INC. | $91.03 | 2022-2023 | Valtoco |
| Catalyst Pharmaceuticals, INC. | $85.12 | 2022-2024 | Fycompa |
| Octapharma USA, INC. | $74.30 | 2024-2025 | Panzyga |
| Scilex Pharmaceuticals INC. | $74.19 | 2024 | |
| Amneal Pharmaceuticals LLC | $73.57 | 2022-2023 | Rytary |
| Amgen INC. | $68.36 | 2022-2024 | Aimovig, Uplizna |
| Genentech USA, INC. | $66.08 | 2024 | Ocrevus |
| Impel Pharmaceuticals INC. | $63.68 | 2023 | Trudhesa |
| Novo Nordisk INC | $54.85 | 2022-2025 | Wegovy, Ozempic, Rybelsus |
| Xeris Pharmaceuticals, INC. | $48.65 | 2024 | Gvoke Hypopen |
| Mallinckrodt Hospital Products INC. | $47.41 | 2024 | Acthar |
| Supernus Pharmaceuticals, INC. | $31.48 | 2023 | Qelbree |
| Corium, LLC | $30.44 | 2023-2024 | Azstarys |
| Sunovion Pharmaceuticals INC. | $25.55 | 2022 | |
| Tanabe Pharma America, INC. | $20.79 | 2023 | |
| Biogen, INC. | $20.07 | 2023 | Aduhelm |
| Jazz Pharmaceuticals INC. | $17.56 | 2023 | Epidiolex |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.40 | 2024 | Xifaxan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jared Ellis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.